CN116806144A - 放射性核素络合物的稳定制剂 - Google Patents

放射性核素络合物的稳定制剂 Download PDF

Info

Publication number
CN116806144A
CN116806144A CN202180078162.5A CN202180078162A CN116806144A CN 116806144 A CN116806144 A CN 116806144A CN 202180078162 A CN202180078162 A CN 202180078162A CN 116806144 A CN116806144 A CN 116806144A
Authority
CN
China
Prior art keywords
pharmaceutical composition
ascorbic acid
sodium ascorbate
radiolabeled
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180078162.5A
Other languages
English (en)
Chinese (zh)
Inventor
塞巴斯蒂安·马克思
奥利弗·莱布
卢克·希梅斯
埃琳娜·玛丽亚·安德烈奥利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Itm Soluxin Co ltd
Original Assignee
Itm Soluxin Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itm Soluxin Co ltd filed Critical Itm Soluxin Co ltd
Publication of CN116806144A publication Critical patent/CN116806144A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202180078162.5A 2020-11-25 2021-11-24 放射性核素络合物的稳定制剂 Pending CN116806144A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2020/083363 2020-11-25
PCT/EP2020/083363 WO2022111800A1 (en) 2020-11-25 2020-11-25 Stable formulations for radionuclide complexes
PCT/EP2021/082812 WO2022112323A1 (en) 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes

Publications (1)

Publication Number Publication Date
CN116806144A true CN116806144A (zh) 2023-09-26

Family

ID=73598128

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180078162.5A Pending CN116806144A (zh) 2020-11-25 2021-11-24 放射性核素络合物的稳定制剂

Country Status (8)

Country Link
US (2) US20240374732A1 (https=)
EP (1) EP4251213A1 (https=)
JP (1) JP2023552180A (https=)
KR (1) KR20230134472A (https=)
CN (1) CN116806144A (https=)
AU (1) AU2021388832A1 (https=)
CA (1) CA3171753A1 (https=)
WO (2) WO2022111800A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120733077A (zh) * 2025-09-01 2025-10-03 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
US20250099634A1 (en) 2023-09-25 2025-03-27 Novartis Ag Method of treating cancer
WO2025255398A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
US12343409B1 (en) * 2024-06-05 2025-07-01 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US10596278B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
PL2970345T3 (pl) 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
US10756278B2 (en) 2017-07-18 2020-08-25 Purdue Research Foundation In situ thermal control of langmuir-schaefer transfer
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US10596278B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUANG LIU等: "Ascorbic Acid: Useful as a Buffer Agent and Radiolytic Stabilizer for Metalloradiopharmaceuticals", 《BIOCONJUGATE CHEM.》, vol. 14, 31 December 2003 (2003-12-31), pages 1052 - 1056 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120733077A (zh) * 2025-09-01 2025-10-03 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂
CN120733077B (zh) * 2025-09-01 2025-12-05 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂

Also Published As

Publication number Publication date
AU2021388832A1 (en) 2023-06-08
WO2022111800A1 (en) 2022-06-02
JP2023552180A (ja) 2023-12-14
WO2022112323A1 (en) 2022-06-02
KR20230134472A (ko) 2023-09-21
US20240374732A1 (en) 2024-11-14
CA3171753A1 (en) 2022-06-02
US12605447B2 (en) 2026-04-21
US20250170243A1 (en) 2025-05-29
EP4251213A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US12605447B2 (en) Stable formulations for radionuclide complexes
JP7436512B2 (ja) 腎保護物質としてのパラアミノ馬尿酸（ｐａｈ）
EP4065176B1 (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
Aloj et al. Radiolabeling approaches for cholecystokinin B receptor imaging
WO2025218931A1 (en) Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
CA3171718C (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2804349C2 (ru) Парааминогиппуровая кислота (паг) как вещество для защиты почек
RU2842991C1 (ru) Комбинация пара-аминогиппуровой кислоты (паг) и меченных радиоактивным изотопом комплексов, предназначенная для лечения рака
HK40078095B (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095A (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
KR20230163487A (ko) 항egfr 항체의 방사성 복합체 및 방사성 의약
HK40065088B (en) Para-aminohippuric acid (pah) as a renal protective substance
HK40065088A (en) Para-aminohippuric acid (pah) as a renal protective substance
Francesconi et al. Metal‐Based Imaging Agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination